Ocular Therapeutix, Inc. (OCUL)
NASDAQ: OCUL · Real-Time Price · USD
9.24
+0.05 (0.54%)
At close: Aug 10, 2026, 4:00 PM EDT
9.25
+0.01 (0.11%)
After-hours: Aug 10, 2026, 5:42 PM EDT
Ocular Therapeutix Revenue
Ocular Therapeutix had revenue of $13.48M in the quarter ending June 30, 2026, with 0.12% growth. This brings the company's revenue in the last twelve months to $52.05M, down -8.14% year-over-year. In the year 2025, Ocular Therapeutix had annual revenue of $51.95M, down -18.47%.
Revenue (ttm)
$52.05M
Revenue Growth
-8.14%
P/S Ratio
38.96
Revenue / Employee
$160,169
Employees
325
Market Cap
2.03B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 51.95M | -11.77M | -18.47% |
| Dec 31, 2024 | 63.72M | 5.28M | 9.03% |
| Dec 31, 2023 | 58.44M | 6.95M | 13.49% |
| Dec 31, 2022 | 51.49M | 7.97M | 18.32% |
| Dec 31, 2021 | 43.52M | 26.12M | 150.08% |
| Dec 31, 2020 | 17.40M | 13.18M | 311.71% |
| Dec 31, 2019 | 4.23M | 2.24M | 112.41% |
| Dec 31, 2018 | 1.99M | 67.00K | 3.48% |
| Dec 31, 2017 | 1.92M | 36.00K | 1.91% |
| Dec 31, 2016 | 1.89M | 137.00K | 7.83% |
| Dec 31, 2015 | 1.75M | 978.00K | 126.68% |
| Dec 31, 2014 | 772.00K | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | 10.00K | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Aurinia Pharmaceuticals | 311.51M |
| Agios Pharmaceuticals | 98.34M |
| AbCellera Biologics | 66.17M |
| Mesoblast | 65.38M |
| Nanobiotix | 38.27M |
| Stoke Therapeutics | 27.59M |
| Zenas BioPharma | 10.00M |
| Taysha Gene Therapies | 7.47M |
OCUL News
- 3 days ago - Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 7 days ago - Ocular Therapeutix reports Q2 EPS (35c), consensus (39c) - TheFly
- 7 days ago - Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights - GlobeNewsWire
- 7 days ago - Ocular Therapeutix Earnings release: Q2 2026 - Filings
- 7 days ago - Ocular Therapeutix Quarterly report: Q2 2026 - Filings
- 8 days ago - Ocular Therapeutix Slides: Study Result presentation - Filings
- 19 days ago - Ocular Therapeutix Transcript: H.C. Wainwright 6th Annual Ophthalmology Virtual Conference - Transcripts
- 25 days ago - Ocular Therapeutix Slides: American Society of Retina Specialists presentation - Filings